An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atara Biotherapeutics (NASDAQ: ATRA) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A live conference call and webcast will follow at 4:30 p.m. EST, where the company will discuss financial results and corporate updates. Atara is a leader in T-cell immunotherapy, focusing on allogeneic Epstein-Barr virus (EBV) T-cell platforms for treating cancer and autoimmune diseases. The company is advancing multiple therapies, with a promising pipeline including tab-cel, currently in Phase 3 development for EBV-driven post-transplant lymphoproliferative disease.
Positive
Upcoming announcement of Q3 2022 financial results may provide insights into company performance.
Lead program tab-cel is in Phase 3 development, indicating progress in therapy development.
Negative
None.
Live Conference Call and Webcast at 4:30 p.m. EST
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2022 financial results after market close on Tuesday, November 8, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EST to discuss the Company’s financial results and provide a corporate update.
Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13733805. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 30 days following the live webcast.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
When will Atara Biotherapeutics release its Q3 2022 financial results?
Atara Biotherapeutics will release its Q3 2022 financial results on November 8, 2022, after market close.
What time is the Atara Biotherapeutics conference call?
The conference call will take place at 4:30 p.m. EST on November 8, 2022.
How can I access the Atara Biotherapeutics conference call?
The conference call can be accessed by dialing 877-407-8291 for domestic callers or 201-689-8345 for international callers, using conference ID 13733805.
What is the status of Atara's lead program, tab-cel?
Tab-cel is currently in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease.
